Check-Cap Regains Nasdaq Compliance Ahead of Merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Newsfilter
- Compliance Regained: Check-Cap Ltd. has received written confirmation from the Nasdaq Listing Qualifications Department that it has regained compliance with Nasdaq's minimum shareholders' equity requirements, establishing a crucial foundation for its merger with MBody AI.
- Merger Progress: The merger received approximately 98% shareholder approval and is expected to transform Check-Cap into a publicly traded leader in embodied artificial intelligence, further enhancing its position in the rapidly growing AI market.
- Technology Platform Advantage: MBody AI's MBody AI Orchestrator™ platform is already deployed across robotic systems at multiple Fortune 500 companies, delivering real-time data intelligence and AI-driven performance insights, thereby strengthening Check-Cap's competitive edge in the market.
- Leadership Outlook: Both Check-Cap and MBody AI leadership expressed that the confirmation of compliance provides strong support for the final stages of the merger, indicating that the company is poised to play a significant role in future technological transformations.
Analyst Views on MBAI
About MBAI
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
